Login
Super Investors Deep Track Capital, LP
DT

Deep Track Capital, LP

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$6.14B
Positions
74
Quarter ended
September 30, 2026
Filed
November 16, 2026

Reported portfolio value by quarter (20 quarters reported)

$6.87B $1.42B
Q4 21 Q4 22 Q4 23 Q4 24 Q4 25 Q3 26

$1.42B in Q4 2021 → $6.14B now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
Guardant Health Inc 8.2% Trimmed 17% 2,805,677 $500M
Biomarin Pharmaceutical Inc 6.2% Added 93% 6,374,395 $382M
Immunovant Inc 5.0% Trimmed 1.9% 9,160,801 $309M
Tarsus Pharmaceuticals Inc 4.9% Added 3.8% 3,806,768 $299M
Veradermics Inc 3.8% Trimmed 5.0% 1,900,000 $230M
VT Vera Therapeutics Inc 3.7% Added 75% 7,000,000 $226M
Vaxcyte Inc 3.3% Trimmed 18% 3,513,069 $200M
Alkermes PLC 3.0% Added 13% 4,500,000 $182M
Ocular Therapeutix Inc 2.7% Added 11% 21,939,625 $168M
UT United Therapeutics Corp Del 2.6% Added 143% 300,040 $163M
Structure Therapeutics Inc 2.5% Added 5.5% 5,000,000 $156M
Grail Inc 2.5% Trimmed 40% 1,104,200 $155M
Insmed Inc 2.5% New 1,350,000 $154M
Compass Pathways PLC 2.5% Unchanged 12,161,496 $151M
Genmab A/s 2.4% Trimmed 26% 4,182,689 $149M
Axsome Therapeutics Inc. 2.4% Added 14% 800,000 $148M
Nurix Therapeutics Inc 2.3% Trimmed 22% 6,000,000 $142M
Lb Pharmaceuticals Inc 2.1% Unchanged 3,352,804 $129M
Tango Therapeutics Inc 1.8% Added 7.1% 4,500,000 $112M
Maze Therapeutics Inc 1.8% Added 9.4% 4,083,969 $111M
HT Hemab Therapeutics Hldgs Inc 1.8% Trimmed 0.4% 3,587,796 $111M
Genmab A/s Call 1.6% Trimmed 8.0% 2,760,000 $98.5M
Moonlake Immunotherapeutics 1.5% Added 16% 8,105,290 $94.8M
Oruka Therapeutics Inc 1.5% Trimmed 44% 1,069,774 $89.1M
Genedx Holdings Corp 1.4% Added 71% 1,200,000 $86.8M
Tempus Ai Inc Call 1.3% New 1,000,000 $81.9M
Cogent Biosciences Inc 1.3% Added 25% 2,500,000 $80.1M
Gh Research PLC 1.3% Unchanged 3,333,334 $78.3M
Bicara Therapeutics Inc 1.2% Unchanged 4,100,000 $76.3M
LB Latigo Biotherapeutics Inc 1.2% New 4,408,322 $73.6M
CT Celldex Therapeutics Inc New 1.1% Trimmed 28% 2,125,532 $68.9M
Bridgebio Pharma Inc 0.9% New 885,882 $58.3M
Avalo Therapeutics Inc 0.9% Unchanged 3,610,000 $55.3M
Alumis Inc 0.9% Added 18% 7,469,746 $55.2M
Altimmune Inc 0.9% Unchanged 19,250,000 $55.1M
AT Attovia Therapeutics Inc 0.9% New 3,207,138 $55M
Billiontoone Inc 0.9% New 500,000 $53.2M
Aclaris Therapeutics Inc 0.8% Unchanged 9,345,000 $49.2M
Cormedix Inc 0.8% Unchanged 6,274,076 $48.3M
Edgewise Therapeutics Inc 0.8% New 1,148,817 $46.6M
Verastem Inc 0.8% Unchanged 5,740,850 $46.2M
Definium Therapeutics Inc 0.6% Trimmed 64% 1,000,000 $38.1M
Generate Biomedicines Inc 0.6% Added 88% 2,507,449 $37.7M
Mbx Biosciences Inc 0.6% Trimmed 63% 640,000 $37.5M
Ani Pharmaceuticals Inc 0.6% New 500,000 $36.3M
VT Viridian Therapeutics Inc 0.6% Trimmed 52% 1,711,030 $35.2M
Harrow Inc 0.5% Added 10% 1,069,000 $32.9M
Obsidian Therapeutics Inc 0.5% New 2,120,050 $29.1M
Corvus Pharmaceuticals Inc 0.5% Unchanged 2,491,939 $28.7M
Neurocrine Biosciences Inc 0.5% New 200,000 $28.4M
Solid Biosciences Inc 0.4% Unchanged 3,565,062 $25.8M
Shattuck Labs Inc 0.4% Unchanged 3,706,734 $25.3M
Beam Therapeutics Inc 0.4% Unchanged 1,000,000 $24.5M
Mannkind Corp 0.3% Trimmed 16% 5,030,522 $19.6M
Xenon Pharmaceuticals Inc 0.3% New 500,000 $18.6M
Olema Pharmaceuticals Inc 0.3% Added 41% 2,109,951 $18.2M
Nektar Therapeutics 0.3% Unchanged 300,000 $18.2M
Design Therapeutics Inc 0.3% New 1,323,986 $16.6M
Century Therapeutics Inc 0.3% Unchanged 9,462,645 $16.2M
Dyne Therapeutics Inc Call 0.3% New 1,000,000 $16.1M

Showing top 60 of 74 positions.

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 16, 2026

Company Action Shares changed Value of change % of portfolio
Alnylam Pharmaceuticals Inc Exited −825,000 −$248M —
Nuvalent Inc Exited −1,783,322 −$220M —
Biomarin Pharmaceutical Inc Added +3,066,914 +$184M 6.2%
Ionis Pharmaceuticals Inc Exited −2,200,000 −$174M —
Insmed Inc New +1,350,000 +$154M 2.5%
Guardant Health Inc Trimmed −587,635 −$105M 8.2%
Grail Inc Trimmed −730,744 −$102M 2.5%
VT Vera Therapeutics Inc Added +3,000,000 +$96.9M 3.7%
UT United Therapeutics Corp Del Added +176,424 +$95.6M 2.6%
Tempus Ai Inc New +1,000,000 +$81.9M 1.3%

Showing the 10 largest of 69 changes.

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
SS SPDR Series Trust Exited −10,000,000 −$1.28B —
Alnylam Pharmaceuticals Inc New +825,000 +$248M 3.6%
Veradermics Inc Added +1,500,000 +$184M 3.6%
Apellis Pharmaceuticals Inc Exited −4,532,374 −$182M —
HT Hemab Therapeutics Hldgs Inc New +3,602,093 +$132M 1.9%
Centessa Pharmaceuticals PLC Exited −3,158,041 −$125M —
Biomarin Pharmaceutical Inc Added +2,157,481 +$123M 2.8%
Axsome Therapeutics Inc. Trimmed −400,000 −$97.9M 2.5%
Gh Research PLC New +3,333,334 +$89.6M 1.3%
Immunovant Inc Trimmed −2,185,820 −$84.2M 5.2%

Showing the 10 largest of 71 changes.

Q1 2026

quarter ended March 31, 2026 · filed May 15, 2026

Company Action Shares changed Value of change % of portfolio
Dynavax Technologies Corp Exited −15,726,349 −$242M —
Alumis Inc New +6,772,595 +$149M 2.4%
Nuvalent Inc New +1,376,324 +$141M 2.3%
Apellis Pharmaceuticals Inc Trimmed −3,217,626 −$129M 3.0%
Cytokinetics Inc Trimmed −1,962,678 −$129M 1.5%
Ocular Therapeutix Inc Added +11,615,868 +$98.4M 2.7%
Genmab A/s New +3,663,250 +$98.3M 1.6%
Biomarin Pharmaceutical Inc Trimmed −1,150,000 −$65M 1.1%
Definium Therapeutics Inc New +3,000,000 +$56.7M 0.9%
Alkermes PLC Added +1,590,323 +$56.2M 2.1%

Showing the 10 largest of 61 changes.

Q4 2025

quarter ended December 31, 2025 · filed February 13, 2026

Company Action Shares changed Value of change % of portfolio
SS SPDR Series Trust New +10,000,000 +$1.22B 21.7%
Terns Pharmaceuticals Inc Trimmed −6,725,952 −$272M 0.6%
Akero Therapeutics Inc Exited −4,000,978 −$190M —
Ionis Pharmaceuticals Inc Trimmed −2,108,144 −$167M 2.4%
VT Vera Therapeutics Inc New +2,821,135 +$143M 2.5%
Guardant Health Inc Trimmed −1,354,086 −$138M 5.1%
89bio Inc Exited −9,356,171 −$138M —
Biomarin Pharmaceutical Inc Added +2,275,144 +$135M 2.4%
Protagonist Therapeutics Inc Exited −1,715,691 −$114M —
VT Viridian Therapeutics Inc Trimmed −2,855,616 −$88.9M 1.4%

Showing the 10 largest of 68 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 14, 2025

Company Action Shares changed Value of change % of portfolio
Insmed Inc Exited −1,750,000 −$176M —
Protagonist Therapeutics Inc Trimmed −1,530,208 −$102M 3.2%
Tarsus Pharmaceuticals Inc Added +1,250,000 +$74.3M 5.0%
Ionis Pharmaceuticals Inc Trimmed −1,083,400 −$70.9M 7.0%
Exact Sciences Corp New +1,000,000 +$54.7M 1.5%
Lb Pharmaceuticals Inc New +3,352,804 +$52.9M 1.5%
UP Ultragenyx Pharmaceutical In Exited −1,350,000 −$49.1M —
Akero Therapeutics Inc Added +958,380 +$45.5M 5.3%
Dianthus Therapeutics Inc Exited −2,233,148 −$41.6M —
Cytokinetics Inc Added +650,000 +$35.7M 6.6%

Showing the 10 largest of 67 changes.

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
IT Intra-cellular Therapies Inc Exited −2,000,000 −$264M —
Insmed Inc Added +1,495,249 +$150M 5.6%
Axsome Therapeutics Inc New +801,371 +$83.7M 2.7%
Bridgebio Pharma Inc Trimmed −1,900,000 −$82M 1.2%
Guardant Health Inc Trimmed −1,193,721 −$62.1M 7.1%
Vaxcyte Inc Added +1,400,000 +$45.5M 2.2%
Amgen Inc Exited −113,035 −$35.2M —
Apellis Pharmaceuticals Inc Added +2,000,000 +$34.6M 3.9%
Edgewise Therapeutics Inc Exited −1,400,000 −$30.8M —
Jade Biosciences Inc New +2,509,301 +$25.1M 0.8%

Showing the 10 largest of 57 changes.

Q1 2025

quarter ended March 31, 2025 · filed May 15, 2025

Company Action Shares changed Value of change % of portfolio
Springworks Therapeutics Inc Exited −3,460,756 −$125M —
Protagonist Therapeutics Inc Added +2,000,000 +$96.7M 4.7%
Ionis Pharmaceuticals Inc Added +2,630,279 +$79.4M 4.5%
Tarsus Pharmaceuticals Inc New +1,484,266 +$76.2M 2.5%
Akero Therapeutics Inc Added +1,720,270 +$69.6M 4.2%
Bridgebio Pharma Inc Added +1,980,838 +$68.5M 3.1%
Immunovant Inc Added +3,500,000 +$59.8M 5.3%
Sarepta Therapeutics Inc New +899,731 +$57.4M 1.9%
Geron Corp Added +34,164,964 +$54.3M 2.0%
HB Harmony Biosciences Hldgs In Exited −1,450,000 −$49.9M —

Showing the 10 largest of 59 changes.

Q4 2024

quarter ended December 31, 2024 · filed February 14, 2025

Company Action Shares changed Value of change % of portfolio
Argenx Se Exited −365,000 −$198M —
Verona Pharma PLC Trimmed −2,330,025 −$108M 1.5%
Intellia Therapeutics Inc Exited −4,950,000 −$102M —
Alkermes PLC Exited −3,500,000 −$98M —
Cytokinetics Inc Added +1,870,094 +$88M 4.4%
Axsome Therapeutics Inc Exited −857,219 −$77M —
Dynavax Technologies Corp Added +5,265,000 +$67.2M 8.5%
Apogee Therapeutics Inc Exited −1,000,000 −$58.7M —
HB Harmony Biosciences Hldgs In New +1,450,000 +$49.9M 1.9%
Septerna Inc New +1,912,929 +$43.8M 1.6%

Showing the 10 largest of 76 changes.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support